The FDA has approved a generic version of lenalidomide, a drug used to treat multiple myeloma and myelodysplastic syndromes, with availability set for Jan. 31, 2026.

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...

Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...

Daratumumab plus VRd significantly improves survival in newly diagnosed multiple myeloma, supporting its role as a new ...

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...

A five-year study has found that adding daratumumab (D) to the current standard-of-care triplet therapy bortezomib, lenalidomide, and dexamethasone (VRd) produced deeper and more durable minimal ...

Ciltacabtagene autoleucel improved minimal residual disease negativity and sustained responses vs standard care in ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...